The Ohio State University Dermatology Biorepository

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03146676

Enrollment

175

Registered

2017-05-10

Start date

2017-04-19

Completion date

2030-12-31

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa

Brief summary

This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.

Detailed description

A variety of molecular techniques can be used to investigate diseases by analyzing protein, DNA, and RNA. Flow cytometry, Polymerase chain reaction (PCR), histology and immunohistochemistry are assays which can identify specific cell populations and provide valuable information regarding the pathologic characteristics of those populations. Flow cytometry analyzes the surface markers of cells. Histology and immunohistochemistry further characterize surface and cellular molecules and aid in the diagnosis of certain skin diseases. Gene expression profiling allows investigators to examine the genes detectable to determine the function of the cells involved, and PCR techniques are useful for the diagnosis of certain conditions and for DNA analysis. By procuring blood, skin tissue, and swab samples from patients with and without neoplastic and inflammatory skin disorders at the time of their appointments, the hypothesize that future translational research can be conducted on such specimens using the aforementioned techniques to further understand disease mechanisms in cutaneous disorders, and to potentially discover defective function and genetic mutations within cells from patients with neoplastic and inflammatory skin disorders. By establishing a tissue bank, we aim to lay the foundation for future work that will improve our understanding of the biology and natural history of neoplastic and inflammatory cutaneous diseases.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Seen by an Ohio State University (OSU) Dermatology provider on the main University Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this protocol * Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals * Willingness to participate in a research study.

Exclusion criteria

* Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders	5 years

Countries

United States

Contacts

CONTACTAlison Rocchi

alison.wandling@osumc.edu614-685-0251

CONTACTKristina Susi

Kristina.Susi@osumc.edu614-814-1277

PRINCIPAL_INVESTIGATORBenjamin Kaffenberger, MD

Dermatologist

Outcome results